Institutions & Corporations

Equities

Ken Trbovich

Text Size: Decrease Increase
Print
Director
Specialty Pharmaceuticals

Mr. Trbovich is a veteran analyst on Wall Street, who joined Janney in September 2015 after having spent more than 16 years analyzing and publishing research on public companies. Mr. Trbovich’s passion for equity research in general, and health care research in particular, was honed at the Red Chip Review, an independent research firm focused on discovering promising small capitalization companies in the late 1990s. Mr. Trbovich’s experience includes more than a decade following specialty pharmaceutical companies at firms such C.E. Unterberg, Towbin (now Canaccord Genuity) and RBC Capital Markets. He has been twice recognized for his stock picking ability in the pharmaceutical sector. The awards include The Wall Street Journal’s “Best on the Street” in 2006 and Forbes “The Best Analysts” in 2007. Following the market crash in 2009, Mr. Trbovich founded Capital Rx Consulting, where he advised senior management of public and private healthcare companies on capital markets strategy, potential licensing and M&A transactions.

Mr. Trbovich is a CFA charter holder and a member of the CFA Society of Colorado. Mr. Trbovich received an MBA from the Thunderbird School of Global Management and an undergraduate degree in accounting from the University of Arizona.

Acorda Therapeutics (ACOR)
Agile Therapeutics, Inc. (AGRX)
AMAG Pharmaceuticals, Inc. (AMAG)
BioDelivery Sciences International, Inc. (BDSI)
Cara Therapeutics (CARA)
Collegium Pharmaceutical, Inc. (COLL)
DepoMed Inc. (DEPO)
Flexion Therapeutics, Inc. (FLXN)
GW Pharmaceuticals PLC (GWPH)
Impax Laboratories Inc. (IPXL)
Innocoll Holdings PLC (INNL)
Insys Therapeutics, Inc. (INSY)
Jazz Pharmaceuticals Plc (JAZZ)
Pacira Pharmaceuticals, Inc. (PCRX)
Reco Pharma, Inc. (REPH)